The Experts below are selected from a list of 14525781 Experts worldwide ranked by ideXlab platform
Paul I Terasaki - One of the best experts on this subject based on the ideXlab platform.
-
four year follow up of a prospective trial of hla and mica antibodies on kidney graft survival
American Journal of Transplantation, 2007Co-Authors: Paul I Terasaki, Miyuki Ozawa, R CastroAbstract:In 2002, 1329 patients with functioning transplants were prospectively tested for HLA antibodies in the 13th International Histocompatibility Workshop. Four years after testing, deceased donor graft survival among 806 patients not having antibodies in 2002 was 81% compared to 58% for 158 patients with HLA antibodies (p < 0.0001) and 72% for 69 patients with MICA antibodies (p = 0.02). Hazard ratio (HR) using death-censored graft survival from multivariate analysis of HLA antibodies was 3.3 (p < 0.00001) and 2.04 for MICA (p = 0.01). In the 14th Workshop, at 1 year follow-up, survival for 1319 patients receiving deceased donor grafts and no HLA antibodies was 96% compared to 94% for 344 patients with HLA antibodies (p = 0.0004) and 83% survival for 33 patients with MICA (p = 0.0005). HR from multivariate analysis: HLA antibodies was 3.6 (p < 0.00001) and 6.1 for MICA (p = 0.006). Twelve patients with donor specific antibodies tested by single antigen beads had a 1 year survival of 64% (p = 0.008), and 27 patients with non-donor specific ‘strong’ antibodies had a 66% survival (p = 0.0003) compared to 92% survival in those with no antibodies. In conclusion, these two prospective trials, after 1 and 4 years, provided strong evidence that HLA and MICA antibodies are associated with graft failure.
-
predicting kidney graft failure by hla antibodies a prospective trial
American Journal of Transplantation, 2004Co-Authors: Paul I Terasaki, Miyuki OzawaAbstract:HLA antibodies have been shown to be associated with late graft loss of organ transplants in prior studies. Recently they were even shown to appear years BEFORE rejection. (1) An international cooperative study of 4763 patients from 36 centers was undertaken to determine the frequency of HLA antibodies in patients with functional transplants. The overall frequency of HLA antibodies among kidney transplant recipients was 20.9%; 19.3% in the liver, 22.8% in the heart, and 14.2% in the lung. Patients treated with CsA-MMF had significantly lower antibodies (9.8%) than those treated with CsA-Aza (18.1%) (0.00008). (2) Second, a prospective trial was performed in 23 kidney transplant centers to determine whether HLA antibodies could predict failures within 1 year. Among the 2278 patients followed up, 91 grafts failed and 34 patients died. Of 500 patients who had HLA antibodies, 6.6% failed compared with 3.3% among 1778 patients without antibodies (p = 0.0007). Among 244 patients who made de novo antibodies, 8.6% failed compared with 3.0% failures among 1421 patients who did not make antibodies (p = 0.00003). Death occurred in 1.5% of patients and was not associated with antibodies. Thus, after 1 year in this prospective trial, patients with HLA antibodies had graft failure at a significantly higher rate than those without antibodies.
-
predicting kidney graft failure by hla antibodies a prospective trial
American Journal of Transplantation, 2004Co-Authors: Paul I Terasaki, Miyuki OzawaAbstract:HLA antibodies have been shown to be associated with late graft loss of organ transplants in prior studies. Recently they were even shown to appear years BEFORE rejection. (1) An international cooperative study of 4763 patients from 36 centers was undertaken to determine the frequency of HLA antibodies in patients with functional transplants. The overall frequency of HLA antibodies among kidney transplant recipients was 20.9%; 19.3% in the liver, 22.8% in the heart, and 14.2% in the lung. Patients treated with CsA-MMF had significantly lower antibodies (9.8%) than those treated with CsA-Aza (18.1%) (0.00008). (2) Second, a prospective trial was performed in 23 kidney transplant centers to determine whether HLA antibodies could predict failures within 1 year. Among the 2278 patients followed up, 91 grafts failed and 34 patients died. Of 500 patients who had HLA antibodies, 6.6% failed compared with 3.3% among 1778 patients without antibodies (p = 0.0007). Among 244 patients who made de novo antibodies, 8.6% failed compared with 3.0% failures among 1421 patients who did not make antibodies (p = 0.00003). Death occurred in 1.5% of patients and was not associated with antibodies. Thus, after 1 year in this prospective trial, patients with HLA antibodies had graft failure at a significantly higher rate than those without antibodies.
-
adjuvant immunotherapy of resected intermediate thickness node negative melanoma with an allogeneic tumor vaccine impact of hla class i antigen expression on outcome
Journal of Clinical Oncology, 2002Co-Authors: Jeffrey A Sosman, Joseph M Unger, Lawrence E Flaherty, Raymond A Kempf, J. A. Thompson, Paul I Terasaki, Min S. Park, Vernon K SondakAbstract:PURPOSE: An association between expression of ≥ two of five HLA class I antigens (HLA-A2, HLA-A28, HLA-B44, HLA-B45, and HLA-C3; collectively called M5) and response to an allogeneic melanoma vaccine (Melacine; Corixa Corporation, Seattle, WA) has been described in stage IV melanoma. This study investigated whether class I antigen expression impacted relapse-free survival (RFS) after adjuvant therapy with this vaccine. PATIENTS AND METHODS: We performed class I (HLA-A, HLA-B, and HLA-C) serotyping on patients enrolled onto Southwest Oncology Group Trial 9035, a randomized, observation-controlled, phase III trial of adjuvant Melacine. All patients had clinically node-negative cutaneous melanoma (1.5 to 4.0 mm). Interactions between treatment and class I antigen expression were tested. Analyses involved all serotyped patients and were adjusted for tumor thickness, method of nodal staging, sex, ulceration, and primary tumor site. RESULTS: HLA typing was performed on 553 (80%) of the 689 enrolled patients (29...
-
nucleotide sequence analysis of hla b 1523 and b 8101 dominant α helical motifs produce complex serologic recognition patterns for the hla b dt and hla b nm5 antigens
Human Immunology, 1995Co-Authors: Mary Ellexson, G A Teresi, Guozhong Zhang, Dod Stewart, Paul I Terasaki, William H. HildebrandAbstract:Abstract Assigning a precise serologic specificity to the class I HLA-B“NM5” and HLA-B“DT” molecules has proven difficult, with patterns of serologic crossreactivity suggesting that NM5 is most like antigens in the B5 CREG and that DT is either B7 or B40 like. To better understand the relationship these antigens share with other HLA-B molecules we determined the nucleotide sequence of the alleles encoding HLA-B“NM5” and HLA-B“DT”. Sequencing results show that NM5 shares the most overall sequence homology with the B70 antigens and that differences at the α-helical Bw4/Bw6 epitope preclude serologic cross-reactivity between NM5 and the B70 antigens. Accordingly, NM5 has been assigned the name B∗1523. The strong serologic impact of helical sequence conservations and variations is reiterated for the class I HLA-B“DT” molecule. Comparative analysis demonstrates that sequence conservations in the first domain's α-helix stimulate cross-reactivity between HLA-B“DT” and HLA-B7, whereas epitopes conserved in the second domain's α-helix impel cross-reactivity between HLA-B“DT” and HLA-B48. To convey the unique lineage of this hybrid B7/B48 molecule the name HLAB∗8101 has been assigned to HLA-B“DT”.
Miyuki Ozawa - One of the best experts on this subject based on the ideXlab platform.
-
four year follow up of a prospective trial of hla and mica antibodies on kidney graft survival
American Journal of Transplantation, 2007Co-Authors: Paul I Terasaki, Miyuki Ozawa, R CastroAbstract:In 2002, 1329 patients with functioning transplants were prospectively tested for HLA antibodies in the 13th International Histocompatibility Workshop. Four years after testing, deceased donor graft survival among 806 patients not having antibodies in 2002 was 81% compared to 58% for 158 patients with HLA antibodies (p < 0.0001) and 72% for 69 patients with MICA antibodies (p = 0.02). Hazard ratio (HR) using death-censored graft survival from multivariate analysis of HLA antibodies was 3.3 (p < 0.00001) and 2.04 for MICA (p = 0.01). In the 14th Workshop, at 1 year follow-up, survival for 1319 patients receiving deceased donor grafts and no HLA antibodies was 96% compared to 94% for 344 patients with HLA antibodies (p = 0.0004) and 83% survival for 33 patients with MICA (p = 0.0005). HR from multivariate analysis: HLA antibodies was 3.6 (p < 0.00001) and 6.1 for MICA (p = 0.006). Twelve patients with donor specific antibodies tested by single antigen beads had a 1 year survival of 64% (p = 0.008), and 27 patients with non-donor specific ‘strong’ antibodies had a 66% survival (p = 0.0003) compared to 92% survival in those with no antibodies. In conclusion, these two prospective trials, after 1 and 4 years, provided strong evidence that HLA and MICA antibodies are associated with graft failure.
-
predicting kidney graft failure by hla antibodies a prospective trial
American Journal of Transplantation, 2004Co-Authors: Paul I Terasaki, Miyuki OzawaAbstract:HLA antibodies have been shown to be associated with late graft loss of organ transplants in prior studies. Recently they were even shown to appear years BEFORE rejection. (1) An international cooperative study of 4763 patients from 36 centers was undertaken to determine the frequency of HLA antibodies in patients with functional transplants. The overall frequency of HLA antibodies among kidney transplant recipients was 20.9%; 19.3% in the liver, 22.8% in the heart, and 14.2% in the lung. Patients treated with CsA-MMF had significantly lower antibodies (9.8%) than those treated with CsA-Aza (18.1%) (0.00008). (2) Second, a prospective trial was performed in 23 kidney transplant centers to determine whether HLA antibodies could predict failures within 1 year. Among the 2278 patients followed up, 91 grafts failed and 34 patients died. Of 500 patients who had HLA antibodies, 6.6% failed compared with 3.3% among 1778 patients without antibodies (p = 0.0007). Among 244 patients who made de novo antibodies, 8.6% failed compared with 3.0% failures among 1421 patients who did not make antibodies (p = 0.00003). Death occurred in 1.5% of patients and was not associated with antibodies. Thus, after 1 year in this prospective trial, patients with HLA antibodies had graft failure at a significantly higher rate than those without antibodies.
-
predicting kidney graft failure by hla antibodies a prospective trial
American Journal of Transplantation, 2004Co-Authors: Paul I Terasaki, Miyuki OzawaAbstract:HLA antibodies have been shown to be associated with late graft loss of organ transplants in prior studies. Recently they were even shown to appear years BEFORE rejection. (1) An international cooperative study of 4763 patients from 36 centers was undertaken to determine the frequency of HLA antibodies in patients with functional transplants. The overall frequency of HLA antibodies among kidney transplant recipients was 20.9%; 19.3% in the liver, 22.8% in the heart, and 14.2% in the lung. Patients treated with CsA-MMF had significantly lower antibodies (9.8%) than those treated with CsA-Aza (18.1%) (0.00008). (2) Second, a prospective trial was performed in 23 kidney transplant centers to determine whether HLA antibodies could predict failures within 1 year. Among the 2278 patients followed up, 91 grafts failed and 34 patients died. Of 500 patients who had HLA antibodies, 6.6% failed compared with 3.3% among 1778 patients without antibodies (p = 0.0007). Among 244 patients who made de novo antibodies, 8.6% failed compared with 3.0% failures among 1421 patients who did not make antibodies (p = 0.00003). Death occurred in 1.5% of patients and was not associated with antibodies. Thus, after 1 year in this prospective trial, patients with HLA antibodies had graft failure at a significantly higher rate than those without antibodies.
Anna Ghirardello - One of the best experts on this subject based on the ideXlab platform.
-
idiopathic recurrent acute pericarditis familial mediterranean fever mutations and disease evolution in a large cohort of caucasian patients
Lupus, 2005Co-Authors: Antonio Brucato, Yael Shinar, G Brambilla, L Robbiolo, G Ferrioli, Maria Cristina Patrosso, D Zanni, Silvana Penco, E Boiani, Anna GhirardelloAbstract:Idiopathic recurrent acute pericarditis (IRAP) is suspected to be an autoimmune phenomenon. We studied 46 consecutive patients. We looked for: 1) the occurrence of new diagnoses of autoimmune diseases during our follow up; 2) HLA typing; and 3) the presence of the most frequent mutations linked to familial Mediterranean fever (FMF gene or MEFV). HLA typing was done in 21 patients at loci B, DRB1, DQA1 and DQB1. MEFV gene was looked in 23 patients using specific primers. During the follow-up we made a new diagnosis of primary Sjogren’s syndrome in four patients (8.7%) and of rheumatoid arthritis in one patient (2.2%). HLA B14, DRB1*01 and DQB1*0202 were significantly more prevalent, but we did not find a typical HLA typing. MEFV gene was searched: exon 10 was checked by sequence and the E148Q mutation by restriction site analysis. No mutations were found. In conclusion, the prevalence of definite immunorheumatological diseases and the absence of the mutations linked to FMF reinforce the notion that idiopat...
-
idiopathic recurrent acute pericarditis familial mediterranean fever mutations and disease evolution in a large cohort of caucasian patients
Lupus, 2005Co-Authors: Antonio Brucato, Yael Shinar, G Brambilla, L Robbiolo, G Ferrioli, Maria Cristina Patrosso, D Zanni, Silvana Penco, E Boiani, Anna GhirardelloAbstract:Idiopathic recurrent acute pericarditis (IRAP) is suspected to be an autoimmune phenomenon. We studied 46 consecutive patients. We looked for: 1) the occurrence of new diagnoses of autoimmune diseases during our follow up; 2) HLA typing; and 3) the presence of the most frequent mutations linked to familial Mediterranean fever (FMF gene or MEFV). HLA typing was done in 21 patients at loci B, DRB1, DQA1 and DQB1. MEFV gene was looked in 23 patients using specific primers. During the follow-up we made a new diagnosis of primary Sjogren's syndrome in four patients (8.7%) and of rheumatoid arthritis in one patient (2.2%). HLA B14, DRB1*01 and DQB1*0202 were significantly more prevalent, but we did not find a typical HLA typing. MEFV gene was searched: exon 10 was checked by sequence and the E148Q mutation by restriction site analysis. No mutations were found. In conclusion, the prevalence of definite immunorheumatological diseases and the absence of the mutations linked to FMF reinforce the notion that idiopathic acute recurrent pericarditis is an autoimmune condition.
Gregory A. Poland - One of the best experts on this subject based on the ideXlab platform.
-
hla alleles associated with the adaptive immune response to smallpox vaccine a replication study
Human Genetics, 2014Co-Authors: Inna G Ovsyannikova, Richard B. Kennedy, Shane V Pankratz, Hannah M. Salk, Gregory A. PolandAbstract:We previously reported HLA allelic associations with vaccinia virus (VACV)-induced adaptive immune responses in a cohort of healthy individuals (n = 1,071 subjects) after a single dose of the licensed smallpox (Dryvax) vaccine. This study demonstrated that specific HLA alleles were significantly associated with VACV-induced neutralizing antibody (NA) titers (HLA-B*13:02, *38:02, *44:03, *48:01, and HLA-DQB1*03:02, *06:04) and cytokine (HLA-DRB1*01:03, *03:01, *10:01, *13:01, *15:01) immune responses. We undertook an independent study of 1,053 healthy individuals and examined associations between HLA alleles and measures of adaptive immunity after a single dose of Dryvax-derived ACAM2000 vaccine to evaluate previously discovered HLA allelic associations from the Dryvax study and determine if these associations are replicated with ACAM2000. Females had significantly higher NA titers than male subjects in both study cohorts [median ID50 discovery cohort 159 (93, 256) vs. 125 (75, 186), p < 0.001; replication cohort 144 (82, 204) vs. 110 (61, 189), p = 0.024]. The association between the DQB1*03:02 allele (median ID50 discovery cohort 152, p = 0.015; replication cohort 134, p = 0.010) and higher NA titers was replicated. Two HLA associations of comparable magnitudes were consistently found between DRB1*04:03 and DRB1*08:01 alleles and IFN-γ ELISPOT responses. The association between the DRB1*15:01 allele with IFN-γ secretion was also replicated (median pg/mL discovery cohort 182, p = 0.052; replication cohort 203, p = 0.014). Our results suggest that smallpox vaccine-induced adaptive immune responses are significantly influenced by HLA gene polymorphisms. These data provide information for functional studies and design of novel candidate smallpox vaccines.
-
hla supertypes and immune responses to measles mumps rubella viral vaccine findings and implications for vaccine design
Vaccine, 2007Co-Authors: Inna G Ovsyannikova, Robert M Jacobson, Shane V Pankratz, Robert A Vierkant, Gregory A. PolandAbstract:Although the outcome of the immune response to measles-mumps-rubella (MMR) vaccination depends on multiple factors, elucidation of specific host genetic markers, such as HLA supertypes based on a shared sequence motif in the peptide-binding pockets of HLA molecules, is essential. We studied the association between measures of humoral and cellular immune responses and HLA supertypes among 346 children previously immunized with two doses of MMR. We found that HLA supertypes, such as A3, B7, B44, B58, B62, and DR may play a role in modulating immune responses to the measles and mumps components of MMR vaccine. This information may be of significant value in the engineering of potential epitope-based vaccines that are recognized by T cells restricted by human HLA supertype alleles.
-
the association of class i hla alleles and antibody levels after a single dose of measles vaccine
Human Immunology, 2003Co-Authors: Robert M Jacobson, Gregory A. Poland, Shane V Pankratz, Daniel J Schaid, Robert A Vierkant, Steven J Jacobsen, Jennifer L St Sauver, Breanndan S MooreAbstract:Abstract Despite the success of the current measles vaccine in controlling disease in industrialized countries, the importance of vaccine failure has become increasingly apparent. Our objective was to determine if associations exist between seronegativity after measles vaccination and class I human leukocyte antigen (HLA) alleles. We undertook a cross-sectional observational study in Rochester, Minnesota, with 242 school-age children previously recruited from a communitywide seroprevalence study. We studied two groups of subjects: 72 were seronegative (EIA ≤0.8 after a single dose of measles vaccine) and 170 were seropositive (enzyme immunoassy [EIA] ≥1.0 after one dose). We used the resources of Mayo Clinic’s tissue typing laboratory for serotyping class I HLA-A and HLA-B alleles via microlymphocytotoxicity assays. We found no statistically significant associations with class I HLA-A but did find associations with class I HLA-B, which includes alleles associated with seronegativity (B8, B13, and B44) and those associated with seropositivity (B7 and B51). Elucidation of the specific peptide-HLA complex interactions that lead to varying or failed immune responses may provide fertile groundwork for improved vaccines that can overcome limitations of the current live, attenuated measles vaccine.
-
the association between hla class i alleles and measles vaccine induced antibody response evidence of a significant association
Vaccine, 1998Co-Authors: Gregory A. Poland, Robert M Jacobson, Daniel J Schaid, Breanndan S Moore, Steven J JacobsenAbstract:While the Moraten strain measles vaccine is an excellent, safe, and immunogenic vaccine, vaccine failure occurs, presumably when an individual develops an inadequate immune response. In this study, we examined the association of HLA class I genes and measles vaccine-induced antibody levels. We found that the allele distribution of HLA-B alleles differed between non-responders and hyper-responders (p = 0.002). Several class I alleles were associated with non-response (HLA-B13, -B44, and -C5); whereas several other alleles were associated with hyper-response (HLA-B7 and -B51). In addition, non-responders were more likely to be HLA-B homozygous than normal responders (odds ratio 2.1), and more likely to be homozygous than hyper-responders (odds ratio 3.7, p = 0.031 Mantel-Haenzel for trend). Finally, we found evidence of an allele dose-response phenomenon for HLA-B7. We conclude that there are important associations between class I HLA genes and measles antibody levels following immunization.
Soldano Ferrone - One of the best experts on this subject based on the ideXlab platform.
-
heterogeneity in the anti hla dr immune response elicited by the antiidiotypic monoclonal antibody f5 444 analysis at the clonal level
Transplantation, 1992Co-Authors: Sara M Mariani, Elena A Armandola, Soldano FerroneAbstract:A total of 630 hybridomas were generated from a BALB/c mouse immunized with the anti-id mAb F5-444, which binds an idiotope within the antigen-combining site of mAb AC1.59. The latter recognizes a determinant shared by HLA-DR1, DRw8, DR9 antigens and subtypes of HLA-DR4 and DR6 that is poorly expressed by HLA-DRw16 and DRw17 antigens. Eight anti-anti-id mAb were shown with serological and immunochemical assays to react with HLA-DR antigens. Detailed analysis of these anti-HLA-DR anti-anti-id mAb showed that they differ from the original anti-HLA-DR mAb AC1.59 and among themselves in either isotype, fine specificity, extent of reactivity with the nominal antigen, differential reactivity with soluble or cell-bound antigen, and/or idiotype profile. These observations emphasize the need to characterize a panel of antigen-binding anti-anti-id mAb in order to evaluate the degree of similarity existing between antigen-binding antibodies induced by an anti-id mAb and the original antigen-binding mAb.
-
diversity of anti hla dr antibodies elicited by distinct anti idiotypic monoclonal antibodies recognizing idiotopes co expressed by the immunizing monoclonal antibody
Immunology, 1992Co-Authors: Sara M Mariani, Elena A Armandola, Soldano FerroneAbstract:Analysis at the clonal level of the idiotypic network has identified differences in fine specificity between antigen-binding anti-anti-idiotypic (anti-anti-id) monoclonal antibody (mAb) and the original mAb as well as among antigen-binding anti-anti-idiotypic (anti-id) mAb. However, the diversity of humoral immune responses elicited by anti-id mAb recognizing idiotopes co-expressed on the immunizing mAb has not been analysed. Since this information may contribute to our understanding of the role of anti-id antibodies in the generation of diversity in the course of an immune response, we have compared the fine specificity and idiotype profile of two subsets of anti-HLA-DR mAb generated with the anti-id mAb F5-444 and F5-830. The latter mAb recognize idiotopes co-expressed in the antigen-combining site of the immunizing anti-HLA-DR1,4,w14,w8,9 mAb AC1.59. These investigations showed that: (1) the two subsets of anti-HLA-DR mAb overlap only partially in their reactivity patterns with HLA-DR+ cells; (2) both subsets of anti-HLA-DR mAb recognize spatially close epitopes; (3) each subset of anti-HLA-DR mAb has unique reactivity patterns with soluble HLA-DRw16 and DRw17 antigens; and (4) each subset of anti-anti-id mAb displays a distinct idiotype profile. The subtle differences in the fine specificity and idiotype profile of the two subsets of anti-HLA-DR mAb suggest that anti-id antibodies may play a role in the generation of diversity in the course of a humoral immune response.